BRIEF-Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program After Strong Positive Phase 2 Results

Pfizer

Pfizer

PFE

0.00

May 20 (Reuters) - Pfizer Inc PFE.N:

  • PFIZER: ADVANCES PIVOTAL PEDIATRIC PNEUMOCOCCAL VACCINE PROGRAM FOLLOWING STRONG POSITIVE PHASE 2 RESULTS

  • PFIZER: 25VPNC PHASE 2 DATA SHOWS ROBUST IMMUNOGENICITY, INCLUDING ENHANCED RESPONSE AGAINST SEROTYPE 3, WITH EXPANDED PROTECTION ACROSS 25 SEROTYPES

  • PFIZER: 25VPNC WELL-TOLERATED WITH NO SAFETY CONCERNS IDENTIFIED IN PHASE 2 STUDY

  • PFIZER: INITIATED ITS PHASE 3 25VPNC PEDIATRIC PROGRAM

  • PFIZER: ABOUT 9 TO 15-FOLD HIGHER SEROTYPE 3 IMMUNOGENICITY RESPONSE AFTER DOSE 3 & 4 IN INFANTS RECEIVING 25VPNC VERSUS PREVNAR 20

  • PFIZER: 25VPNC EXPECTED TO COVER UP TO 90% OF DISEASE-CAUSING SEROTYPES IN CHILDREN UNDER AGE OF 5, INCLUDING ABOUT 15% FROM SEROTYPE 3

  • PFIZER: ADULT PNEUMOCOCCAL VACCINE CANDIDATE EXPECTED TO ENTER CLINICAL DEVELOPMENT BY END OF 2026

Further company coverage: PFE.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.